The pharmaceutical community is read more excited by retatrutide, a new dual GIP and GLP-1 target that’s showing significant results in early studies . This medication works by mimicking natural hormones to affect appetite and boost feelings of satisfaction , ultimately resulting in considerable weight decrease. While still under review and not r